Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) is now available.
Hemogenyx Pharmaceuticals has announced the administration of its first-in-human dose of HG-CT-1, a proprietary CAR-T cell therapy, for treating relapsed or refractory acute myeloid leukemia (R/R AML) in adults. This marks a significant milestone in their clinical development program, highlighting progress toward providing a potentially life-saving treatment for AML patients with limited options.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded clinical-stage biopharmaceutical company headquartered in London, with US subsidiaries located in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases and aims to expand the use of bone marrow transplantation for patients with life-threatening conditions. Hemogenyx is working on several product candidates and a platform technology to drive novel product development.
YTD Price Performance: -21.60%
Average Trading Volume: 19,569
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £11.44M
For an in-depth examination of HEMO stock, go to TipRanks’ Stock Analysis page.